Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
P/B ratio for Viking Therapeutics, Inc. (VKTX)
P/B ratio as of 2023: 5.04
According to Viking Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.04. At the end of 2022 the company had a P/B ratio of 4.97.
P/B ratio history for Viking Therapeutics, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 5.04 |
| 2022 | 4.97 |
| 2021 | 1.76 |
| 2020 | 1.67 |
| 2019 | 2.08 |
| 2018 | 1.48 |
| 2017 | 7.83 |
| 2016 | 2.41 |
| 2015 | 2.48 |
| 2014 | -1.56 |
| 2013 | -137.59 |
| 2012 | -0.11 |